Ionis Pharmaceuticals announces availability of press release on ION337 ASCEND study in Dravet syndrome

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

0.00
  • Ionis reported first dosing in ASCEND, a Phase 1-2 study of ION337 in children with Dravet syndrome.
  • Trial evaluates safety, tolerability; includes 6-month single-ascending dose followed by 24-month multiple-ascending dose with dosing every 6 months.
  • ION337 is an RNA-targeted antisense medicine using Ionis’ NMA chemistry, designed to boost potency and support infrequent intrathecal dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.